DU Qian,XI Xin,DONG Jie,et al.Pharmacy active consultation:an innovative model of hospital pharmaceutical services[J].ZHONGGUO YAOFANG,2022,33(21):2666-2670.
DU Qian,XI Xin,DONG Jie,et al.Pharmacy active consultation:an innovative model of hospital pharmaceutical services[J].ZHONGGUO YAOFANG,2022,33(21):2666-2670. DOI: 10.6039/j.issn.1001-0408.2022.21.19.
Pharmacy active consultation:an innovative model of hospital pharmaceutical services
Pharmacy active consultation refers to the spontaneous activity that clinical pharmacists take the initiative to go to clinical departments to help doctors solve problems related to drug use in clinical practice,put forward drug treatment suggestions or provide pharmaceutical services,and form medical documents. The difference between pharmacy active consultation and pharmacy consultation is that the latter is generally proposed by the clinician,who sends a consultation invitation to the pharmacy department in the hospital information system,and the clinical pharmacist will go to the consultation after receiving it,while the former is a pharmaceutical service mode that the clinical pharmacist takes the initiative to carry out in the clinical department. On the basis of routine pharmacy active consultation,clinical pharmacists in our hospital also further carried out a special active consultation mode (including prompt special active consultation for patients with multidrug resistance bacteria positive,active monitoring and intervention for patients with drug-induced liver injury),and patient pharmaceutical supervision in the form of return visit of pharmacy active consultation. Pharmacy active consultation and its special active consultation possess the characteristics of initiative,early and extensive coverage,as a supplement to resident clinical pharmacy services. Pharmacy active consultation could help the pharmacy department to improve service efficiency,provide a new perspective for medical institutions to carry out efficient pharmaceutical services,and supply new ideas for the reform of pharmaceutical services in China.
AITHAL G P,WATKINS P B,ANDRADE R J,et al. Case definition and phenotype standardization in drug-induced liver injury[J]. Clin Pharmacol Ther,2011,89(6):806-815.
Council for International Organizations of Medical Sciences (CIOMS). Drug-induced liver injury (DILI):Current status and future directions for drug development and the post-market setting[EB/OL]. (2020-08-21)[2022-02-01]. https://cioms.ch/wp-content/uploads/2020/06/CIOMS_ DILI_Web_16Jun2020.pdfhttps://cioms.ch/wp-content/uploads/2020/06/CIOMS_DILI_Web_16Jun2020.pdf.
Analysis of Drug Use for Rare Gefitinib-caused Liver Injury Complicated with Cholecystitis in a Patient with Lung Adenocarcinoma by Clinical Pharmacists